Precision Epigenomics logo
  • EPISEEK
  • Solutions
    • Individuals 45+
    • Firefighters
    • Pancreatic Cancer Test
  • Resources
    • FAQ
    • News
  • About
  • Contact
  • Order EPISEEK Now $699
Get EPISEEK $699
EPISEEK Cancer Test: Could a Simple Blood Draw Catch Cancer Early?

EPISEEK Cancer Test: Could a Simple Blood Draw Catch Cancer Early?

by Megan Ross | Nov 9, 2026 | Healthcare

We’re pleased to be recognized by the Arizona Daily Star in a recent column by Ken Cook, “U of A spinout takes aim at cancer.” Here’s a summary of the story, with a link to the full article below. In the 1940s, about 1 in 16 people were diagnosed with cancer at some...
Precision Epigenomics Recognized at the 2026 AZBio Awards for Advancing Multi-Cancer Early Detection

Precision Epigenomics Recognized at the 2026 AZBio Awards for Advancing Multi-Cancer Early Detection

by Megan Ross | Nov 5, 2026 | Healthcare, News

Precision Epigenomics has been named a 2026 AZBio Awards Fast Lane honoree, recognizing its progress in molecular diagnostics and the development of EPISEEK® Multi-Cancer Early Detection, an innovative blood-based test designed to detect more than 60 types of cancer....
New Clinical Test Developed to Accurately Classify Pleural Effusions

New Clinical Test Developed to Accurately Classify Pleural Effusions

by Amy Cook | Nov 20, 2025 | Healthcare, News

Precision Epigenomics presents EPISEEK®-MPE clinical data at Association for Molecular Pathology (AMP). Tucson, AZ —  Precision Epigenomics, a molecular diagnostics company developing next-generation epigenetic assays, today announced new results from a study...
Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond

Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond

by Amy Cook | Oct 15, 2025 | Healthcare, News

Read Molika Ashford’s full article here. Or check out the summary below:  Tucson, AZ — Precision Epigenomics is taking a deliberate, tactical approach as it advances its EPISEEK® test in the blood-based cancer screening field. While continuing to offer its...
Precision Epigenomics Joins the Conversation: Key Takeaways from Rosetta Fest

Precision Epigenomics Joins the Conversation: Key Takeaways from Rosetta Fest

by Amy Cook | Oct 14, 2025 | Healthcare, News

Tucson, AZ — The Precision Epigenomics team recently had an engaging and insightful experience at the Hint Summit at Rosetta Fest, a premier gathering for leaders in direct patient care. The conference served as a powerful platform for fostering collaboration and...
Precision Epigenomics Named “Startup of the Year” by University of Arizona, Honored for Pioneering Early Cancer Detection Technology

Precision Epigenomics Named “Startup of the Year” by University of Arizona, Honored for Pioneering Early Cancer Detection Technology

by Amy Cook | Oct 9, 2025 | Healthcare, News

Tucson, AZ — Precision Epigenomics, a molecular diagnostics innovator transforming cancer care, proudly announced today that it has been honored with the Startup of the Year award by the University of Arizona at the annual I-Squared conference. The prestigious award...
« Older Entries

Recent Posts

  • EPISEEK Cancer Test: Could a Simple Blood Draw Catch Cancer Early?
  • Precision Epigenomics Recognized at the 2026 AZBio Awards for Advancing Multi-Cancer Early Detection
  • Precision Epigenomics Announces Unprecedented Early-Stage Sensitivity Data for EPISEEK® Multi-Cancer Early Detection Test
  • Industry Excitement: GenomeWeb Survey Confirms High Interest in MCED Tests
  • Precision Epigenomics and Front Line Mobile Health to Deliver EPISEEK Cancer Testing to First Responders in TX, CO, & GA

Recent Comments

No comments to show.

The EPISEEK® test is recommended for use in adults with an elevated risk for cancer, such as those aged 45 or older. The EPISEEK test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK is intended to detect cancer signals. Use of EPISEEK is not recommended in individuals who are pregnant or are planning to become pregnant in the next three months, younger than 21 years old, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected does not completely rule out cancer. A test result of Abnormal Methylation Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (i.e. imaging and lab testing) to confirm or exclude the presence of cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK false positive) or confirmatory testing was insufficient to detect a very early cancer (follow up testing false negative). False positive (abnormal methylation signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Quick Links

Home
About
Tests
Resources
News
Contact

FAQ

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way
Ste 280B
Tucson, AZ 85711



520.372.7522



520.777.7367

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow